Overview and Scope
Acute coronary syndrome (ACS) refers to a range of clinical manifestations caused by abrupt, decreased blood flow to the heart. Symptoms of ACS include chest pain or discomfort (angina), shortness of breath, dizziness and other signs of heart-related distress. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications.

Sizing and Forecast
The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.23 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $12.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%.  The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Segmentation & Regional Insights
The acute coronary syndrome market covered in this report is segmented –
1) By Type: Non-St-Elevation Myocardial Infarction; St-Elevation Myocardial Infarction; Unstable Angina
2) By Treatment: Medications; Statins; Beta blockers; ACE inhibitors; Anticoagulants; Other Treatment
3) By Diagnosis: Stress Test; Blood Tests; Imaging; Other Diagnosis
4) By Route Of Administration: Oral; Parenteral
5) By End-User: Hospitals; Specialty clinics; Other End User

North America was the largest region in the acute coronary syndrome market in 2023. The regions covered in acute coronary syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases is expected to propel the growth of the acute coronary syndrome market going forward. Ischemic heart disease is a chronic disease caused by the obstruction or narrowing of the coronary arteries. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications for patients suffering from various acute coronary syndromes, including ischemic heart disease and vascular diseases. For instance, in August 2022, according to a study published in the Journal of the American College of Cardiology, a US-based organization, all four cardiovascular risk factors are anticipated to rise among the general U.S. population between 2025 and 2060, dyslipidemia increased by 27.6%, and hypertension by 25.1%. The researchers discovered that heart failure (33.4%) and ischemic heart disease (30.7%) had the biggest anticipated increases in rates, followed by heart attack (16.9%) and stroke (33.8%). Therefore, the prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases drives the acute coronary syndrome market.

Key Industry Players
Major players in the acute coronary syndrome market are  Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

The acute coronary syndrome market report table of contents includes:
1. Executive Summary
2. Acute Coronary Syndrome Market Characteristics
3. Acute Coronary Syndrome Market Trends And Strategies
4. Acute Coronary Syndrome Market - Macro Economic Scenario
5. Global Acute Coronary Syndrome Market Size and Growth
…..
32. Global Acute Coronary Syndrome Market Competitive Benchmarking
33. Global Acute Coronary Syndrome Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Acute Coronary Syndrome Market
35. Acute Coronary Syndrome Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:
https://topprnews.com/artificial-intelligence-platforms-market-size/
https://topprnews.com/pharmacy-automation-systems-system-market-size/
https://topprnews.com/physiological-monitors-market-growth/
https://goodprnews.com/video-measuring-system-market-growth/
https://goodprnews.com/connected-drug-delivery-devices-market-trends/
https://goodprnews.com/twister-winder-market-forecast/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model